[Comparison of the Predictive Value of Padua and the IMPEDE Assessment Scores for Venous Thromboembolism in Patients with Newly Diagnosed Multiple Myeloma: A Single Institution Experience]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2023 Aug 7

PMID 37550189

Authors

L J Fang

X D Yao

M Q Lu

B Chu

L Shi

S Gao

Q Q Xiang

Y T Wang

X Liu

Y H Ding

Y Chen

M Z Wang

X Zhao

W K Hu

K Sun

L Bao

Affiliations

Soon will be listed here.

Abstract

To compare the predictive efficacy of the two thrombosis risk assessment scores (Padua and IMPEDE scores) in venous thromboembolism (VTE) within 6 months in patients with newly diagnosed multiple myeloma (NDMM) in China. This study reviewed the clinical data of 421 patients with NDMM hospitalized in Beijing Jishuitan Hospital from April 2014 to February 2022. The sensitivity, specificity, accuracy, and Youden index of the two scores were calculated to quantify the thrombus risk assessment of VTE by the Padua and IMPEDE scores. The receiver operating characteristics curves of the two evaluation scores were drawn. The incidence of VTE was 14.73%. The sensitivity, specificity, accuracy, and Youden index of the Padua score were 100%, 0%, 14.7%, and 0% and that of the IMPEDE score was 79%, 44%, 49.2%, and 23%, respectively. The areas under the curve of Padua and IMPEDE risk assessment scores were 0.591 and 0.722, respectively. IMPEDE score is suitable for predicting VTE within 6 months in patients with NDMM.

References

Guo H, Zhou X, Jiang Y, Yang G, Sun C, Zhuang Y . Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience. Am J Hematol. 2010; 85(7):499-501. DOI: 10.1002/ajh.21734. View

Chalayer E, Teste A, Guyotat D, Elalamy I, Leleu X, Tardy B . Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score. Am J Hematol. 2019; 95(1):E18-E20. DOI: 10.1002/ajh.25658. View

Kristinsson S, Pfeiffer R, Bjorkholm M, Goldin L, Schulman S, Blimark C . Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010; 115(24):4991-8. PMC: 2890150. DOI: 10.1182/blood-2009-11-252072. View

Covut F, Ahmed R, Chawla S, Ricaurte F, Samaras C, Anwer F . Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. Br J Haematol. 2021; 193(6):1213-1219. DOI: 10.1111/bjh.17505. View

Fulkerson W, Coleman R, Ravin C, Saltzman H . Diagnosis of pulmonary embolism. Arch Intern Med. 1986; 146(5):961-7. View

Zheng W, Wei G, Ye X, He J, Li L, Wu W . Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. Leuk Res. 2009; 33(12):1615-8. DOI: 10.1016/j.leukres.2009.04.006. View

Wang G, Yang G, Huang Z, Zhong Y, Jin F, Liao A . [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma]. Zhonghua Nei Ke Za Zhi. 2017; 56(7):500-506. DOI: 10.3760/cma.j.issn.0578-1426.2017.07.006. View

White R, Zhou H, Romano P . Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003; 90(3):446-55. DOI: 10.1160/TH03-03-0152. View

Fallouh N, McGuirk H, Flanders S, Chopra V . Peripherally Inserted Central Catheter-associated Deep Vein Thrombosis: A Narrative Review. Am J Med. 2015; 128(7):722-38. DOI: 10.1016/j.amjmed.2015.01.027. View

10.

Xue K, Qiu L, Liu T, Hou J, Huang X, Ma J . [A multi-centers clinical study of different treatment outcomes of 332 patients with multiple myeloma]. Zhonghua Nei Ke Za Zhi. 2008; 47(2):98-101. View

11.

Palumbo A, Rajkumar S, Dimopoulos M, Richardson P, San Miguel J, Barlogie B . Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2007; 22(2):414-23. DOI: 10.1038/sj.leu.2405062. View

12.

Yu Y, Gau J, Liu C, Yang M, Chiang S, Hsu H . A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. Thromb Haemost. 2012; 108(2):225-35. DOI: 10.1160/TH12-01-0010. View

13.

Fernandes C, Morinaga L, Alves Jr J, Castro M, Calderaro D, Jardim C . Cancer-associated thrombosis: the when, how and why. Eur Respir Rev. 2019; 28(151). PMC: 9488553. DOI: 10.1183/16000617.0119-2018. View

14.

Bradbury C, Craig Z, Cook G, Pawlyn C, Cairns D, Hockaday A . Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood. 2020; 136(9):1091-1104. PMC: 7453153. DOI: 10.1182/blood.2020005125. View

15.

Callander N, Baljevic M, Adekola K, Anderson L, Campagnaro E, Castillo J . NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022; 20(1):8-19. DOI: 10.6004/jnccn.2022.0002. View

16.

Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M . A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010; 8(11):2450-7. DOI: 10.1111/j.1538-7836.2010.04044.x. View

17.

Fotiou D, Sergentanis T, Papageorgiou L, Stamatelopoulos K, Gavriatopoulou M, Kastritis E . Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma:.... Blood Cancer J. 2018; 8(11):102. PMC: 6221885. DOI: 10.1038/s41408-018-0135-y. View

18.

Kristinsson S, Pfeiffer R, Bjorkholm M, Schulman S, Landgren O . Thrombosis is associated with inferior survival in multiple myeloma. Haematologica. 2012; 97(10):1603-7. PMC: 3487563. DOI: 10.3324/haematol.2012.064444. View

19.

Sanfilippo K, Luo S, Wang T, Fiala M, Schoen M, Wildes T . Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019; 94(11):1176-1184. PMC: 7058359. DOI: 10.1002/ajh.25603. View

20.

Rajkumar S, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M . Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2009; 11(1):29-37. PMC: 3042271. DOI: 10.1016/S1470-2045(09)70284-0. View